Bortezomib enhances expression of effector molecules in antitumor CD8+T lymphocytes by promoting Notch-nuclear factor-κB crosstalk

Menaka Thounaojam, Duafalia F. Dudimah, Samuel T. Pellom, Roman V. Uzhachenko, David P. Carbone, Mikhail M. Dikov, Anil Shanker

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The immunosuppressive tumor microenvironment usurps host antitumor immunity by multiple mechanisms including interference with the Notch system, which is important for various metazoan cell fate decisions and hematopoietic cell differentiation and function. We observed that treatment with the proteasome inhibitor bortezomib in mice bearing various solid tumors resulted in an upregulated expression of various Notch signaling components in lymphoid tissues, thereby increasing CD8+T-lymphocyte IFNγ secretion and expression of effector molecules, perforin and granzyme B, as well as the T-box transcription factor eomesodermin. Bortezomib also neutralized TGFβ-mediated suppression of IFNγ and granzyme B expression in activated CD8+T-cells. Of note, bortezomib reversed tumor-induced downregulation of Notch receptors, Notch1 and Notch2, as well as increased the levels of cleaved Notch intracellular domain (NICD) and downstream targets Hes1 and Hey1 in tumor-draining CD8+T-cells. Moreover, bortezomib promoted CD8+T-cell nuclear factor-κB (NFκB) activity by increasing the total and phosphorylated levels of the IκB kinase and IκBα as well as the cytoplasmic and nuclear levels of phosphorylated p65. Even when we blocked NFκB activity by Bay-11-7082, or NICD cleavage by γ-secretase inhibitor, bortezomib significantly increased expression of Notch Hes1 and Hey1 genes as well as perforin, granzyme B and eomesodermin in activated CD8+T-cells. Data suggest that bortezomib can rescue tumor-induced dysfunction of CD8+T-cells by its intrinsic stimulatory effects promoting NICD-NFκB crosstalk. These findings provide novel insights on using bortezomib not only as an agent to sensitize tumors to cell death but also to provide lymphocyte-stimulatory effects, thereby overcoming immunosuppressive actions of tumor on anti-tumor T-cell functions.

Original languageEnglish (US)
Pages (from-to)32439-32455
Number of pages17
JournalOncotarget
Volume6
Issue number32
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Complement Factor B
T-Lymphocytes
Neoplasms
Immunosuppressive Agents
Notch Receptors
TCF Transcription Factors
Granzymes
Amyloid Precursor Protein Secretases
Proteasome Inhibitors
Tumor Microenvironment
Lymphoid Tissue
Bortezomib
Cell Differentiation
Immunity
Cell Death
Transcription Factors
Phosphotransferases
Down-Regulation
Lymphocytes
Genes

Keywords

  • Cancer immunosuppression
  • Immune response
  • Immunity
  • Immunology and Microbiology Section
  • NF-κB
  • Notch signaling
  • Proteasome inhibition
  • T cell Immunotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Bortezomib enhances expression of effector molecules in antitumor CD8+T lymphocytes by promoting Notch-nuclear factor-κB crosstalk. / Thounaojam, Menaka; Dudimah, Duafalia F.; Pellom, Samuel T.; Uzhachenko, Roman V.; Carbone, David P.; Dikov, Mikhail M.; Shanker, Anil.

In: Oncotarget, Vol. 6, No. 32, 01.01.2015, p. 32439-32455.

Research output: Contribution to journalArticle

Thounaojam, Menaka ; Dudimah, Duafalia F. ; Pellom, Samuel T. ; Uzhachenko, Roman V. ; Carbone, David P. ; Dikov, Mikhail M. ; Shanker, Anil. / Bortezomib enhances expression of effector molecules in antitumor CD8+T lymphocytes by promoting Notch-nuclear factor-κB crosstalk. In: Oncotarget. 2015 ; Vol. 6, No. 32. pp. 32439-32455.
@article{2b093e56906f4985ad0fb8e017d02b33,
title = "Bortezomib enhances expression of effector molecules in antitumor CD8+T lymphocytes by promoting Notch-nuclear factor-κB crosstalk",
abstract = "The immunosuppressive tumor microenvironment usurps host antitumor immunity by multiple mechanisms including interference with the Notch system, which is important for various metazoan cell fate decisions and hematopoietic cell differentiation and function. We observed that treatment with the proteasome inhibitor bortezomib in mice bearing various solid tumors resulted in an upregulated expression of various Notch signaling components in lymphoid tissues, thereby increasing CD8+T-lymphocyte IFNγ secretion and expression of effector molecules, perforin and granzyme B, as well as the T-box transcription factor eomesodermin. Bortezomib also neutralized TGFβ-mediated suppression of IFNγ and granzyme B expression in activated CD8+T-cells. Of note, bortezomib reversed tumor-induced downregulation of Notch receptors, Notch1 and Notch2, as well as increased the levels of cleaved Notch intracellular domain (NICD) and downstream targets Hes1 and Hey1 in tumor-draining CD8+T-cells. Moreover, bortezomib promoted CD8+T-cell nuclear factor-κB (NFκB) activity by increasing the total and phosphorylated levels of the IκB kinase and IκBα as well as the cytoplasmic and nuclear levels of phosphorylated p65. Even when we blocked NFκB activity by Bay-11-7082, or NICD cleavage by γ-secretase inhibitor, bortezomib significantly increased expression of Notch Hes1 and Hey1 genes as well as perforin, granzyme B and eomesodermin in activated CD8+T-cells. Data suggest that bortezomib can rescue tumor-induced dysfunction of CD8+T-cells by its intrinsic stimulatory effects promoting NICD-NFκB crosstalk. These findings provide novel insights on using bortezomib not only as an agent to sensitize tumors to cell death but also to provide lymphocyte-stimulatory effects, thereby overcoming immunosuppressive actions of tumor on anti-tumor T-cell functions.",
keywords = "Cancer immunosuppression, Immune response, Immunity, Immunology and Microbiology Section, NF-κB, Notch signaling, Proteasome inhibition, T cell Immunotherapy",
author = "Menaka Thounaojam and Dudimah, {Duafalia F.} and Pellom, {Samuel T.} and Uzhachenko, {Roman V.} and Carbone, {David P.} and Dikov, {Mikhail M.} and Anil Shanker",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5857",
language = "English (US)",
volume = "6",
pages = "32439--32455",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

TY - JOUR

T1 - Bortezomib enhances expression of effector molecules in antitumor CD8+T lymphocytes by promoting Notch-nuclear factor-κB crosstalk

AU - Thounaojam, Menaka

AU - Dudimah, Duafalia F.

AU - Pellom, Samuel T.

AU - Uzhachenko, Roman V.

AU - Carbone, David P.

AU - Dikov, Mikhail M.

AU - Shanker, Anil

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The immunosuppressive tumor microenvironment usurps host antitumor immunity by multiple mechanisms including interference with the Notch system, which is important for various metazoan cell fate decisions and hematopoietic cell differentiation and function. We observed that treatment with the proteasome inhibitor bortezomib in mice bearing various solid tumors resulted in an upregulated expression of various Notch signaling components in lymphoid tissues, thereby increasing CD8+T-lymphocyte IFNγ secretion and expression of effector molecules, perforin and granzyme B, as well as the T-box transcription factor eomesodermin. Bortezomib also neutralized TGFβ-mediated suppression of IFNγ and granzyme B expression in activated CD8+T-cells. Of note, bortezomib reversed tumor-induced downregulation of Notch receptors, Notch1 and Notch2, as well as increased the levels of cleaved Notch intracellular domain (NICD) and downstream targets Hes1 and Hey1 in tumor-draining CD8+T-cells. Moreover, bortezomib promoted CD8+T-cell nuclear factor-κB (NFκB) activity by increasing the total and phosphorylated levels of the IκB kinase and IκBα as well as the cytoplasmic and nuclear levels of phosphorylated p65. Even when we blocked NFκB activity by Bay-11-7082, or NICD cleavage by γ-secretase inhibitor, bortezomib significantly increased expression of Notch Hes1 and Hey1 genes as well as perforin, granzyme B and eomesodermin in activated CD8+T-cells. Data suggest that bortezomib can rescue tumor-induced dysfunction of CD8+T-cells by its intrinsic stimulatory effects promoting NICD-NFκB crosstalk. These findings provide novel insights on using bortezomib not only as an agent to sensitize tumors to cell death but also to provide lymphocyte-stimulatory effects, thereby overcoming immunosuppressive actions of tumor on anti-tumor T-cell functions.

AB - The immunosuppressive tumor microenvironment usurps host antitumor immunity by multiple mechanisms including interference with the Notch system, which is important for various metazoan cell fate decisions and hematopoietic cell differentiation and function. We observed that treatment with the proteasome inhibitor bortezomib in mice bearing various solid tumors resulted in an upregulated expression of various Notch signaling components in lymphoid tissues, thereby increasing CD8+T-lymphocyte IFNγ secretion and expression of effector molecules, perforin and granzyme B, as well as the T-box transcription factor eomesodermin. Bortezomib also neutralized TGFβ-mediated suppression of IFNγ and granzyme B expression in activated CD8+T-cells. Of note, bortezomib reversed tumor-induced downregulation of Notch receptors, Notch1 and Notch2, as well as increased the levels of cleaved Notch intracellular domain (NICD) and downstream targets Hes1 and Hey1 in tumor-draining CD8+T-cells. Moreover, bortezomib promoted CD8+T-cell nuclear factor-κB (NFκB) activity by increasing the total and phosphorylated levels of the IκB kinase and IκBα as well as the cytoplasmic and nuclear levels of phosphorylated p65. Even when we blocked NFκB activity by Bay-11-7082, or NICD cleavage by γ-secretase inhibitor, bortezomib significantly increased expression of Notch Hes1 and Hey1 genes as well as perforin, granzyme B and eomesodermin in activated CD8+T-cells. Data suggest that bortezomib can rescue tumor-induced dysfunction of CD8+T-cells by its intrinsic stimulatory effects promoting NICD-NFκB crosstalk. These findings provide novel insights on using bortezomib not only as an agent to sensitize tumors to cell death but also to provide lymphocyte-stimulatory effects, thereby overcoming immunosuppressive actions of tumor on anti-tumor T-cell functions.

KW - Cancer immunosuppression

KW - Immune response

KW - Immunity

KW - Immunology and Microbiology Section

KW - NF-κB

KW - Notch signaling

KW - Proteasome inhibition

KW - T cell Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84946079077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946079077&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5857

DO - 10.18632/oncotarget.5857

M3 - Article

C2 - 26431276

AN - SCOPUS:84946079077

VL - 6

SP - 32439

EP - 32455

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -